As Novel Anticonvulsants

Total Page:16

File Type:pdf, Size:1020Kb

As Novel Anticonvulsants DESIGN AND SYNTHESIS OF SOME ARYLOXYARYL SEMICARBAZONES AND RELATED COMPOUNDS AS NOVEL ANTICONVULSANTS A Thesis Submitted to the College of Graduate Studies and Research in Partial fulfillment of the Requirements for the Degree of Doctor of Philosophy in Pharmacy BY Puthucode Ramanan Narayan Spring 1996 @ Copyright Puthucode Ramanan Narayan, 1996. All rights reserved. National Library Bibliothaue nationale du Canada Acquisitions and Acquisitions et Bibliographic Services sewices bibliographiques 395 Wellington Street 395. rue Wellington OttawaON KIAON4 Ottawa ON KIA ON4 Canada Canada Yarrfi vQtmrd&knw Our t% Norre rdfdrente The author has granted a non- L'auteur a accorde une licence non exclusive licence allowing the exclusive pernettant a la National Library of Canada to Bibliotheque nationale du Canada de reproduce, loan, distribute or sell reproduire, prster, distribuer ou copies of this thesis in microform, vendre des copies de cette these sous paper or electronic formats. la fome de microfiche/fihq de reproduction sur papier ou sur format eectronique. The author retains ownership of the L'auteur conserve la propriete du copyright in this thesis. Neither the droit d'auteur qui protege cette these. thesis nor substantial extracts fiom it Ni la these ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent etre imprimes reproduced without the author's ou auh-ement reproduits sans son permission. autorisation. UNIVERSITY OF SASKATCHEWAN College of Graduate Studies and Research SUMMARY OF DISSERTATION Submitted in partial fulffflment of the requirements for the DEGREE OF DOCTOR OF PHILOSOPEW by Puthucode Ramanan Narayan College of Pharmacy and Nutrition University of Saskatchewan Spring 1996 Examining Committee: Dr. R.T. Card Dean's Designate, Chair College of Gradauate Studies & Research Dr. E. M. Hawes Chair of Advisory Committee College of Pharmacy and Nutrition Dr. J. R Dimmock Supervisor, College of Pharmacy and Nutrition Dr. J. W. Hubbard CoHege of Pharmacy and Nutrition Dr. J. D. Wood Department of Biochemistry Dr. J. M. Tuchek Department of Pharmacology External Examiner: Dr. C. R Clark School of Pharmacy Auburn University Alabama 36849-550 1 USA DESIGN AND SYNTHESIS OF SOME ARYLOXYARYL SEMICARBAZONES AND RELATED COMPOUNDS AS NOVEL ANICONWLSANTS Epilepsy is one of the most common neurological disorders affecting approximately 2% of the world's population. Unfortunately, currently available drugs are effenive in only 65% of the patients and their use may be associated with sigdicant side effects causing disability with considerable socioeconomic implications. Thus. there is an urgent need for new antiepileptic drugs with greater efficacy, specificity and lower toxicity. The development of new antiepileptic drugs remains a challenging problem. since both the prirnw pathologies of epilepsy and the precise mechanisms by which available anticonvulsants act are not well understood- Therefore. the search for new antiepileptic drugs continues to be an active area of investigation in medicinal chemistry. Previous studies revealed that a number of aryl sernicarbazones on oral administration to rats possessed signilicant anticonvulsant activity (ED5, figures in the 20-25 mgkg range) in the MES screen. In addition some of these compounds displayed good protection indices (PI viz. TDr&Dr, of appro-uirnately 25). Lf the aryl sernicarbazones displaying activity in the MES screen interact at a specific binding site. it is likely that the semicarbazono group and the aryl ring align at complementq areas on a macromolecular complex in vivo which have been referred to as the hydrogen bonding area and the aql binding site respectively (Fig. 1). Auxilianr Bindina Area Awl Bindina Site Hvdmsen bond in^ Area Fig. 1 Proposed binding site of aryl semicarbazoncs The principal aim of the study was to investigate the area around the postulated aryl binding site. which is shown in Fig. I as the ausiliaxy binding area with the main view of improving the potency. Ideally an ED5()of 1-3 mg/kg when administered orally to rats will be achieved. The biodata generated on these compounds may afford a clearer picture of the nature of the postulated binding site. A number of axyloxyaqd semicarbazones and related compounds WUE synthesized and evaluated for anticonvulsant activities. After intraperitoneal injection to mice, the Semicart,azones were examined in the MES , scPTZ and neurotoxicity screens. The resuits indicated that greater protection was obtained in the MES test than the scPrZ screen Quantitation of approximately one-third of the compounds revealed an average protection index of approximately 9. After oral administration to rats, a number of compounds displayed significant potencies in the MES screen (EDM of 1-5 mgkg) accompanied by very high protection indices. In fact over half the compounds had PI figures of greater than 100 and four were in excess of 200 and two compounds displayad protection &dices greater than 300. These compounds are ranked very high in terms of pure activity. A number of compounds displayed greater potencies and PI figures in the mouse intraperitoneal and rat oral screens than three clinically used drugs viz phenytoin, cubamazepine and valproate. Patent protection for these novel semicarbazones were made at the US Patent Oifice on June 7, 1995. The data generated fiom these studies supported a binding site hypothesis. Quantitative structure-activity relationships indicated a number of physicochemicaf parameters which contributed to activity in the MES screen X-ray crystallography and moiecular modeling of five compounds suggested the importance of certain interatomic distances and bond angles for activity in the mouse and rat MES screens. In presenting this thesis in partial fulfdment of the requirements for a postgraduate degree from the University of Saskatchewan, I agree that the libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor who supervised my thesis work or, in his absence, by the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis. Request for permission to copy or to make other use of material in this thesis in whole or part should be addressed to : Dean of the College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, CANADA S7N SC9 TO PARENTS, MEMORY OF MOTHER-lN-LAW, WIFE SHREEDEVI AND DAUGEmR SHALINI ACKNOWLEDGMENTS There are many people to whom I owe a debt of gratitude for the help I received throughout the course of this project. First and foremost, I wish to sincerely thank Dr. J. R Dirnmock for his personal interest, guidance, and encouragement during the course of the research work and in the preparation of this thesis. I acknowledge the appropriate suggestions provided to me by the members of my advisory committee: Dr. E. M. Hawes, Dr. J. W. Hubbard, Dr. J. M. Tuchek and Dr. J. D. Wood. I would especially like to express my appreciation to Dr. S. N. Rao, Dr. J. M. Tuchek and Dr. V. Gopal for the time they devoted towards my academic and research endeavors. The rich facilities and the Eendly atmosphere that were bestowed on me by the College of Pharmacy and Nutrition, University of Saskatchewan are also acknowledged. I would like to thank Nordic Merrell Dow Research, Laval, PQ, Canada, for financial suppon of this project and Mr. J. P. Stables (NDlJ for generating most of the biological data. Appreciation is recorded to Dr. J. W. Quail, Dr. L. Prasad and Mrs. U. Pugazhenthi for assistance in the interpretation of the X-ray clystdographic data. My thanks are also due to C. Savithi, M. A. Saeed, (Department of Chemistry), A Lo, L M. Smith, C. Thomson (summer students), and M. Hetherington for their contributions to my research project. The timely help offered by K. G. Tischler, N. M. Kandepu, H. V. Raghuram, H. Jyothsna, V. Iowkin and V. Khanna are greatly appreciated. I also extend my thanks to all my colleagues for their cooperation throughout this work. Finally I would like to thank all my family members especially my wife Shreedevi and daughter Shalini for their love, patience and understanding during the long months of intense labor needed to complete this task. They provided the comfort and support necessary to sustain the human psyche that science never can grant. ABSTRACT Epilepsy is one of the most common neurological disorders affecting approximately 2% of the world's population. Unfortunately, currently available drugs aneffective in only 65% of the patients and their use may be associated with significant side effects causing disability with considerable socioeconomic implications. In addition, between 10 and 25 % of epileptic patients have chronic intractable seizures that are inadequately controlled with the currently available antiepileptic drugs. Thus, there is an urgent need for new antiepileptic drugs with greater efficacy, specificity and lower toxicity. The development of new antiepileptic drugs remains a challenging problem, since both the primary pathologies of epilepsy and the precise mechanisms by which available anticonvulsants act are not well understood. Therefore, the search for new antiepileptic drugs continues to be an active area of investigation in medicinal chemistry. Two major pharmacological screening tests used to evaluate compounds for anticonvulsant activities are the maximal electroshock screen (MES) and the subcutaneous pentylenetetrazol (scPTZ) screen. These tests are claimed to detect compounds possessing activity against generalized tonic-cIonic (grand mal) and generalized absence (petit mal) seizures. The structural requirements for activity in the MES screen have been stat& t; be the presence of a Iarge hydrophobic group which is in close proximity to at least two electron donor atoms.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Pharmacovigilance & Clinical Trials
    Penichet KO, Clin Exp Pharmacol 2012, 2:3 http://dx.doi.org/10.4172/2161-1459.S1.005 International Conference and Exhibition on Pharmacovigilance & Clinical Trials October 1-3, 2012 DoubleTree by Hilton Chicago-North Shore, USA A comparison of the toxicity effects of the anticonvulsant eterobarb and phenobarbital in normal human volunteers Penichet KO New York Medical College, USA enewed corporate interest in the anticonvulsant drug eterobarb justified renewed clinical and experimental interest in this Rdrug. The unique and clinically intriguing feature of eterobarb is that while sharing the anticonvulsant properties of other barbiturates, the hypnotic side effects usually associated with barbiturates appear to be absent in animal studies and greatly reduced in clinical trials. This study was designed to compare the hypnotic effects of eterobarb with those of phenobarbital in healthy normal human volunteers using a double-blind, placebo-controlled design. Both clinical and neuropsychological parameters of toxicity were measured, while blood barbiturate levels were monitored to correlate neurobehavioral changes with total barbiturate level. As expected, there is a linear relationship between the degree of toxicity and the barbiturate level, but much higher barbiturate levels were tolerated without toxicity by subjects taking eterobarb. For ethical reasons, subjects were not maintained at high levels of toxicity over the 10-week trial. However, both eterobarb and phenobarbital recipients failed to show significant improved performance on Digits Total, a test of mental flexibility (Digit Symbol Substitution). In addition, phenobarbital recipients showed the only significant decrement of performance on Digits Total, and they failed to improve significantly on Trails-Part A, in which all other groups improved.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Issue #81-92, 1976
    ISSN 0090-1350 LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedical Communications Network No 81 January 197 THE CONTENTS OF THIS PUBLICATION ARE NOT COPYRIGHTED AND MAY BE FREELY REPRODUCED TABLE OF CONTENTS Page Journal Citation Data Bases 2 On-line Technical Notes 2 Proposed Conversion from TSO to TCAM Message Handler As NLM's Teleprocessing Interface 5 Hedges , 9 Responsible Use of On-line Data Bases 11 An Experiment in On-Site Training, Madison, Wisconsin — December 15-19, 1975 12 Tumor Key Errata 14 MEDLINE Trainees at the University of Wisconsin, December 15, 1975 14 New Serials Announcement - December 1975 15 MEDLINE Trainees at NLM, January 12, 1976 17 U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedlcal Communications Network JOURNAL CITATION DATA BASES EDITOR Grace H. McCarn Head, MEDLARS Management Section MEDLINE and SDILINS were updated with National Library of Medicine February 1976 citations at NLM and SUNY on 8600 Rockville Pike January 12. The sizes, Index Medicus date Bethesda, Maryland 20014 ranges, and entry date ranges are given (301) 496-6193 TWX: 710-824-9616 below: ASSISTANT EDITOR P.E. Pothier MEDLINE (Jan 74 - Feb 76) - 486,93? (Entry Dates: 731130 to 760102) TECHNICAL NOTES EDITOR Leonard J. Bahlman SDILINE (Feb 76) - 21,138 (Entry Dates: 751210 to 761012) The LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN is issued monthly by the Office of the Associate Director for Library Operations. ON-LINE TECHNICAL NOTES PLEASE QUERY THE NLM/ON-LINE NEWS FILES DAILY FOR SPECIAL NOTICES AND MESSAGES Whenever applicable, in the margin beside each Technical Note., users will be referred to the section/page of the NLM On-Line Services Reference Manual which is considered most relevant to the item being discussed (e.g.., Manual II-9) .
    [Show full text]
  • New Antiepileptic Drugs
    TREATMENT OF CHILDREN WITH SEIZURES New antiepileptic drugs ROGER J. PORTER, MD EW medications are the best hope for tens of that could be used to test anticonvulsant activity, the thousands of patients in the United discovery of the antiepileptic effect of bromide and States—and many more worldwide—for phenobarbital was serendipitous. Later, with the devel- control of their epileptic seizures. Only a opment of seizure models, the search for new AEDs was Nfew patients whose disease is currently refractory to based on scientific screening programs. available medications can be considered for surgical The year 1937 marked the beginning of the experi- intervention; other nonmedical therapies such as bio- mental evaluation of promising anticonvulsant chemi- feedback appear to have a similarly limited role. This cals prior to clinical use. Employing a seizure model paper examines a few of the issues related to the based on a new electroshock technique for producing development of new antiepileptic drugs (AEDs) and convulsions in animals,5 Merritt and Putnam6-7 considers some of the data on the most important of screened a group of compounds supplied to them by these new compounds. Current therapy has been re- Parke-Davis and discovered the anticonvulsant proper- viewed in detail elsewhere.1-2 ties of phenytoin, then called diphenylhydantoin. Be- cause phenytoin was well tolerated by laboratory ani- mals, it was subjected to clinical trials in 1938 and EARLY ANTIEPILEPTIC DRUGS marketed that same year. The absence of a sedative effect and the dramatic control of seizures observed In the nineteenth century, bromides were widely when phenytoin was added to barbiturate therapy were used as antiepileptic agents.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • 1. Pubmed Search Strategy for Barbiturates: ("Schizophrenia"[Mesh
    1. PubMed search strategy for barbiturates: ("Schizophrenia"[Mesh] OR "Schizophrenia, Childhood"[Mesh] OR "Schizotypal Personality Disorder"[Mesh] OR "Psychotic Disorders"[Mesh:NoExp] OR "Paranoid Disorders"[Mesh] OR Delusional Disorder*[tiab] OR Psychotic*[tiab] OR Psychosis[tiab] OR Psychoses[tiab] OR Schizoaffective[tiab] OR "Schizo Affective"[tiab] OR Schizophreniform[tiab] OR Schizotyp*[tiab] or Schizophreni*[tiab] OR "Dementia Praecox"[tiab] OR Paranoi*[tiab] OR "Folie a Deux"[tiab] OR "Folie a Trois"[tiab]) AND ("Barbiturates"[Mesh] OR Allobarbital[tiab] OR "Ammonium Purpurate"[tiab] OR Amobarbital[tiab] OR Amsal[tiab] OR Amylobarbitone[tiab] OR Amylobeta[tiab] OR Amytal[tiab] OR Aprobarbital[tiab] OR Barbamyl[tiab] OR Barbexaclone[tiab] OR Barbit*[tiab] OR Barotal[tiab] OR Benzobarbital[tiab] OR Bomathal[tiab] OR Brallobarbital[tiab] OR Brevimytal[tiab] OR Brevital[tiab] OR Brietal[tiab] OR Bucolome[tiab] OR Butalbital[tiab] OR Butethal[tiab] OR Cyclobarbital[tiab] OR Cyclopentobarbital[tiab] OR Desoxyphenobarbital[tiab] OR Diabutal[tiab] OR Dialuric[tiab] OR Diemal[tiab] OR Diethylmalonylurea[tiab] OR Difebarbamate[tiab] OR Dormileno[tiab] OR Etaminal[tiab] OR Eterobarb[tiab] OR Ethaminal[tiab] OR Ethylbarbit*[tiab] OR Eunoctal[tiab] OR Evipan[tiab] OR "Fali Lepsin"[tiab] OR Febarbamate[tiab] OR Gardenal[tiab] OR Heptabarb[tiab] OR Hexenal[tiab] OR Hexobarbit*[tiab] OR Hydroxyphenobarbital[tiab] OR Hysteps[tiab] OR "Isoamitil Sedante"[tiab] OR Isonal[tiab] OR Liskantin[tiab] OR Luminal[tiab] OR Meballymal[tiab] OR Mebaral[tiab]
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]